ZURA Key Statistics, Chart & Performance
The current stock price of ZURA is 5.12 USD. In the past month the price increased by 37.63%. In the past year, price increased by 137.04%.
ZURA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About ZURA
Company Profile
Zura Bio Ltd. is a clinical-stage biotechnology company, which engages in the development of novel medicines for immune disorders. The company is headquartered in La Jolla, California and currently employs 30 full-time employees. The company went IPO on 2021-07-16. The company is developing three assets which have completed Phase I/Ib studies. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
Company Info
ZURA BIO LTD
4225 Executive Square, Suite 600
La Jolla CALIFORNIA US
Employees: 30
Phone: 18582470520
ZURA BIO LTD / ZURA FAQ
Can you describe the business of ZURA BIO LTD?
Zura Bio Ltd. is a clinical-stage biotechnology company, which engages in the development of novel medicines for immune disorders. The company is headquartered in La Jolla, California and currently employs 30 full-time employees. The company went IPO on 2021-07-16. The company is developing three assets which have completed Phase I/Ib studies. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
What is the stock price of ZURA BIO LTD today?
The current stock price of ZURA is 5.12 USD. The price decreased by -2.66% in the last trading session.
What is the dividend status of ZURA BIO LTD?
ZURA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ZURA stock?
ZURA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about ZURA BIO LTD (ZURA) stock?
13 analysts have analysed ZURA and the average price target is 16.32 USD. This implies a price increase of 218.75% is expected in the next year compared to the current price of 5.12.
What is the market capitalization of ZURA stock?
ZURA BIO LTD (ZURA) has a market capitalization of 332.90M USD. This makes ZURA a Small Cap stock.
What is the outstanding short interest for ZURA BIO LTD?
The outstanding short interest for ZURA BIO LTD (ZURA) is 5.53% of its float.
ZURA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ZURA. When comparing the yearly performance of all stocks, ZURA is one of the better performing stocks in the market, outperforming 95.93% of all stocks.
ZURA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ZURA. No worries on liquidiy or solvency for ZURA as it has an excellent financial health rating, but there are worries on the profitability.
ZURA Financial Highlights
Over the last trailing twelve months ZURA reported a non-GAAP Earnings per Share(EPS) of -0.67. The EPS decreased by -4.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.44% | ||
| ROE | -57.76% | ||
| Debt/Equity | 0 |
ZURA Forecast & Estimates
13 analysts have analysed ZURA and the average price target is 16.32 USD. This implies a price increase of 218.75% is expected in the next year compared to the current price of 5.12.